APA (7th ed.) Citation

Uronis, H., Jia, J., Bendell, J., Howard, L., Ready, N., Lee, P., . . . Hurwitz, H. (2015). A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Cancer Chemotherapy & Pharmacology, 75(2), 343. https://doi.org/10.1007/s00280-014-2647-x

Chicago Style (17th ed.) Citation

Uronis, Hope, et al. "A Phase I/biomarker Study of Bevacizumab in Combination with CNTO 95 in Patients with Advanced Solid Tumors." Cancer Chemotherapy & Pharmacology 75, no. 2 (2015): 343. https://doi.org/10.1007/s00280-014-2647-x.

MLA (9th ed.) Citation

Uronis, Hope, et al. "A Phase I/biomarker Study of Bevacizumab in Combination with CNTO 95 in Patients with Advanced Solid Tumors." Cancer Chemotherapy & Pharmacology, vol. 75, no. 2, 2015, p. 343, https://doi.org/10.1007/s00280-014-2647-x.